Induction Therapy with Combination TNF Inhibitor and Methotrexate in Early Rheumatoid Arthritis

RHEUMATOID ARTHRITIS (LW MORELAND, SECTION EDITOR)
Part of the following topical collections:
  1. Topical Collection on Rheumatoid Arthritis

Abstract

With the introduction of more objective disease activity measures and the development of biological therapies, there were dramatic changes in the treatment of rheumatoid arthritis (RA). The combination therapy with tumor necrosis factor (TNF) inhibitor and methotrexate (MTX) has unprecedentedly improved prognosis and outcomes, and very low disease activity or remission has been achievable goal in RA. Although the concept of remission induction and maintenance was first discussed in longstanding RA patients, several clinical trials have demonstrated that there is a therapeutic window of opportunity, and early effective control of inflammation in early RA could lead to less joint damage and better long-term outcomes. Emerging evidence suggests that early combination therapy with TNF inhibitor and MTX leads to rapid clinical remission and thereby improved quality of life. Furthermore, remission status may be sustained in some patients even if a TNF inhibitor is discontinued after sustained remission in early RA patients. While there are many potential benefits of early remission induction therapy with the combination of a TNF inhibitor and MTX, the best therapeutic regimen and strategy for remission induction and maintenance in early RA remain controversial. There are no data to decide a priori when and in whom TNF blocker drugs are indicated in early disease-modifying anti-rheumatic drug (DMARD)-naïve RA.

Keywords

Early rheumatoid arthritis Tumor necrosis factor inhibitor Induction therapy Remission Treatment Combination Methotrexate TNF inhibitor Remission induction Maintenance 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Yong Gil Hwang and Larry W. Moreland declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Prevoo ML, van Riel PL, van’t Hof MA, et al. Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol. 1993;32:589–94.PubMedCrossRefGoogle Scholar
  3. 3.
    Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Smolen JS, Breedveld FC, Eberl G, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum. 1995;38:38–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244–57.CrossRefGoogle Scholar
  6. 6.
    Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56:3226–35.PubMedCrossRefGoogle Scholar
  7. 7.
    Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 2008;58:1310–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906–14.CrossRefGoogle Scholar
  11. 11.
    Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52:2625–36.PubMedCrossRefGoogle Scholar
  12. 12.
    Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54:3761–73.PubMedCrossRefGoogle Scholar
  13. 13.
    Pincus T, Kavanaugh A, Aletaha D, Smolen J. Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol. 2006;24:S-1–6.Google Scholar
  14. 14.
    van Tuyl LH, Vlad SC, Felson DT, Wells G, Boers M. Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum. 2009;61:704–10.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58:2958–67.PubMedCrossRefGoogle Scholar
  16. 16.
    van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis. 2005;64:1582–7.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573–86.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Thiele K, Huscher D, Bischoff S, et al. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1194–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang B, Combe B, Rincheval N, Felson DT. Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort. Arthritis Res Ther. 2012;14:R156.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Sakellariou G, Scire CA, Verstappen SM, Montecucco C, Caporali R. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis. 2013;72:245–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Villeneuve E, Nam J, Emery P. 2010 ACR-EULAR classification criteria for rheumatoid arthritis. Rev Bras Reumatol. 2010;50:481–3.PubMedGoogle Scholar
  22. 22.
    Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford). 2002;41:329–37.CrossRefGoogle Scholar
  23. 23.
    Ji H, Pettit A, Ohmura K, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 2002;196:77–85.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol. 2010;37:2237–46.PubMedCrossRefGoogle Scholar
  25. 25.••
    Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis. 2012;71:989–92. Treatment of very early RA with ETN+MTX provides better clinical outcomes not seen with MTX monotherapy, supporting the pivotal role of TNF inhibition in early disease.PubMedCrossRefGoogle Scholar
  26. 26.
    Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009;68:823–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Gartner M, Mandl P, Radner H, et al. Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission. Arthritis Rheum. 2013;65:2005–14.PubMedCrossRefGoogle Scholar
  28. 28.•
    Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis. 2011;70:315–9. In this analysis, investigators showed infliximab can be discontinued and the majority of relapsed patients can re-achieve clinical remission.PubMedCrossRefGoogle Scholar
  29. 29.
    Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375–82.PubMedCrossRefGoogle Scholar
  30. 30.•
    Heimans L, Wevers-de Boer KV, Visser K, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis. 2013. RA was defined by 2010 criteria. Reasearchers showed that remission is better achieved with early switch to a combination of MTX with ADA if the initial treatment was unsuccessful. Google Scholar
  31. 31.•
    Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2013. This study showed that initial therapy with MTX + high-dose intravenous steroid resulted in good disease control comparable to MTX+IFX therapy in DMARD-naive early RA patients, when combined with a treat-to-target approach. Google Scholar
  32. 32.
    Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis. 2013;72:851–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63:373–82.CrossRefGoogle Scholar
  34. 34.
    Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27–35.PubMedCrossRefGoogle Scholar
  35. 35.
    van den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis. 2011;70:1389–94.PubMedCrossRefGoogle Scholar
  36. 36.
    Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011;70:1039–46.PubMedCrossRefGoogle Scholar
  37. 37.•
    Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72:64–71. Treatment with adalimumab + methotrexate was superiot to methotrexate monotherapy in achieving stable low disease activity and radiographic and functional outcomes in methotrexate-naïve early RA patients.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.••
    Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383:321–32. In this two-stage trial, early combination therapy of adalimumab and methotrexate sufficiently achieved low disease activity and most patients were able to maintain their good response after withdrawal of adalimumab after sustained low disease activity.PubMedCrossRefGoogle Scholar
  39. 39.•
    Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis. 2013;72:844–50. In this German study, a greater reduction in radiographic progression after initial combination therapy with adalimumab and MTX was seen at week 48, even after discontinuation of adalimumab treatment at week 24. However, superiority of clinical response was not sustained after withdrawal of adalimumab treatment.PubMedCrossRefGoogle Scholar
  40. 40.•
    Emery P, Spieler W, Stopinska-Polaszewska M, et al. Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrextate: the PRIZE study. Ann Rheum Dis. 2013;72 Suppl 3:399–1. In contrast to adalimumab and infliximab, withdrawal of etanercept after achieving DAS28 remission led to a rapid loss of the response gained with the initial induction therapy.Google Scholar
  41. 41.
    Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 2004;50:36–42.PubMedCrossRefGoogle Scholar
  42. 42.
    Saleem B, Brown AK, Keen H, et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum. 2009;60:1915–22.PubMedCrossRefGoogle Scholar
  43. 43.•
    Saleem B, Brown AK, Quinn M, et al. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis. 2012;71:1316–21. Smoldering disease activity was witnessed with sensitive imaging modalities in RA patients with disease in remission.PubMedCrossRefGoogle Scholar
  44. 44.
    Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2011;63:1479–85.PubMedCrossRefGoogle Scholar
  45. 45.
    Solomon DH, Bitton A, Katz JN, Radner H, Brown E, Fraenkel L. Treat to target in rheumatoid arthritis: fact, fiction or hypothesis? Arthritis Rheum. 2013.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Rheumatology and Clinical ImmunologyUniversity of PittsburghPittsburghUSA

Personalised recommendations